Safety, Tolerability and Immunogenicity Induced by the THV01 Treatment in Patients Infected With HIV-1 Clade B and Treated With Highly Active Antiretroviral Therapy (HAART).

NCT02054286 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infection

Interventions

BIOLOGICAL: THV01-1
BIOLOGICAL: THV01-2
BIOLOGICAL: Placebo

Sponsor

Theravectys S.A.